Floatz logo

PEGFILGRASTIM

Primary Peritoneal Carcinoma

TORL Biotherapeutics, LLCprotein_peptidePhase 2/3Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

148 Active assets in the Primary Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
GOG Foundation
Phase 3BBB
Carboplatin
University of Washington
Phase 3BBB
NOGITECAN
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Adriamycin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Nivestim
Roswell Park Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

PEGFILGRASTIM is also rated in:

neutropeniaDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
diffuse large B-cell lymphomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
non-Hodgkin lymphomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →